BJP Try Advances in Psychiatric Treatment Online
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Psychiatric Bulletin Advances in Psychiatric Treatment All RCPsych Journals
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Goodall, E.
Right arrow Articles by Silverstone, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Goodall, E.
Right arrow Articles by Silverstone, T.

The British Journal of Psychiatry 153: 208-213 (1988)
© 1988 The Royal College of Psychiatrists

A clinical trial of the efficacy and acceptability of D-fenfluramine in the treatment of neuroleptic-induced obesity

E Goodall, C Oxtoby, R Richards, G Watkinson, D Brown and T Silverstone
Academic Unit of Human Psychopharmacology, Medical College, St Bartholomew's Hospital.

Twenty-nine overweight schizophrenic patients maintained on depot neuroleptic injections who wished to lose weight took part in a double- blind, placebo-controlled trial of 30 mg D-fenfluramine. All subjects received dietary advice. Sixteen patients completed the 12-week trial. Rate of weight loss was significantly greater in those taking D- fenfluramine. Side-effects were reported, but no deterioration in mental state was noted.


This article has been cited by other articles:


Home page
 Proc. Natl. Acad. Sci. USAHome page
S. F. Kim, A. S. Huang, A. M. Snowman, C. Teuscher, and S. H. Snyder
From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase
PNAS, February 27, 2007; 104(9): 3456 - 3459.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
C. E Koro, D. O Fedder, G. J L'Italien, S. S Weiss, L. S Magder, J. Kreyenbuhl, D. A Revicki, and R. W Buchanan
Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study
BMJ, August 3, 2002; 325(7358): 243 - 243.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
G. A. Bray and F. L. Greenway
Current and Potential Drugs for Treatment of Obesity
Endocr. Rev., December 1, 1999; 20(6): 805 - 875.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Psychiatric Bulletin Advances in Psychiatric Treatment All RCPsych Journals
Copyright © 1988 The Royal College of Psychiatrists.